Journal of neurosurgery · 2025
Prevalence and risk factors of nonyield brain biopsy: a 21-year experience with robot-assisted stereotactic biopsies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schumacher Xavier, Hudelist Benoit, Paun Luca, Benzakoun Joseph, Demasi Marco, Hamza Meissa, Roux Alexandre, Moiraghi Alessandro, Elia Angela, Parraga Eduardo, Dezamis Edouard, Chretien Fabrice, Varlet Pascale, Oppenheim Catherine, Pallud Johan, Zanello Marc
Аннотация
OBJECTIVE: Magnetic resonance imaging-based, robot-assisted stereotactic brain biopsy is increasingly used worldwide. However, large series reporting nonyield biopsy rates of robot-assisted biopsies are lacking in the literature. The aim of this study was to report a 21-year-long experience on MRI-based, robot-assisted stereotactic biopsy for brain lesions.
METHODS: The records from a single-center, retrospective, and consecutive collection of all adult patients undergoing MRI-based, robot-assisted stereotactic biopsy for a brain lesion in a tertiary neurosurgical center from December 2002 to January 2024 were reviewed.
RESULTS: A total of 911 patients (377 females, mean age at surgery 61.1 ± 16.7 years) were included. Of these patients, 15 (1.6%) had a nonyield biopsy. The nonyield biopsy rate remained stable over the 21-year-long study period (p = 0.224). The nonyield biopsy rate was significantly higher for neurological diseases (4/19, 21.5%) than infectious diseases (1/20, 5.0%) and tumors (10/872, 1.1%) (p < 0.001). There were significantly more nonyield biopsies for deep-seated lesions (8/261, 3.1%) than for superficial lesions (6/612, 1.0%) (p = 0.025) and non-contrast-enhanced lesions (6/99, 6.1%) than in contrast-enhanced lesions (9/797, 1.1%) (p < 0.001). Patients in the nonyield biopsy group had significantly smaller lesions on both contrast-enhanced 3D T1-weighted sequences (1.9 ± 2.2 vs 27.1 ± 29.5 cm3, p = 0.046) and FLAIR sequences (14.0 ± 17.0 vs 80.7 ± 73.3 cm3, p < 0.001). Preoperative corticosteroid administration (407/911, 44.7%; with the bias that corticosteroids were avoided in patients with suspected lymphoma), number of biopsy samples (mean 4.9 ± 2.4), neurosurgeon experience, and WHO classification versions were not associated with a higher risk of nonyield biopsy (p = 0.274, p = 0.053, p = 0.968, and p = 0.366, respectively).
CONCLUSIONS: MRI-based, robot-assisted stereotactic biopsy led to a low rate of nonyield biopsy. Neurological disease, non-contrast-enhanced lesions, and deep-seated lesions were more at risk of nonyield biopsy.
METHODS: The records from a single-center, retrospective, and consecutive collection of all adult patients undergoing MRI-based, robot-assisted stereotactic biopsy for a brain lesion in a tertiary neurosurgical center from December 2002 to January 2024 were reviewed.
RESULTS: A total of 911 patients (377 females, mean age at surgery 61.1 ± 16.7 years) were included. Of these patients, 15 (1.6%) had a nonyield biopsy. The nonyield biopsy rate remained stable over the 21-year-long study period (p = 0.224). The nonyield biopsy rate was significantly higher for neurological diseases (4/19, 21.5%) than infectious diseases (1/20, 5.0%) and tumors (10/872, 1.1%) (p < 0.001). There were significantly more nonyield biopsies for deep-seated lesions (8/261, 3.1%) than for superficial lesions (6/612, 1.0%) (p = 0.025) and non-contrast-enhanced lesions (6/99, 6.1%) than in contrast-enhanced lesions (9/797, 1.1%) (p < 0.001). Patients in the nonyield biopsy group had significantly smaller lesions on both contrast-enhanced 3D T1-weighted sequences (1.9 ± 2.2 vs 27.1 ± 29.5 cm3, p = 0.046) and FLAIR sequences (14.0 ± 17.0 vs 80.7 ± 73.3 cm3, p < 0.001). Preoperative corticosteroid administration (407/911, 44.7%; with the bias that corticosteroids were avoided in patients with suspected lymphoma), number of biopsy samples (mean 4.9 ± 2.4), neurosurgeon experience, and WHO classification versions were not associated with a higher risk of nonyield biopsy (p = 0.274, p = 0.053, p = 0.968, and p = 0.366, respectively).
CONCLUSIONS: MRI-based, robot-assisted stereotactic biopsy led to a low rate of nonyield biopsy. Neurological disease, non-contrast-enhanced lesions, and deep-seated lesions were more at risk of nonyield biopsy.